Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Genetic toxicity: in vitro

Currently viewing:

Administrative data

Endpoint:
in vitro gene mutation study in bacteria
Remarks:
Type of genotoxicity: gene mutation
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP. Guideline study

Data source

Reference
Reference Type:
other: Body responsible for the test
Title:
Unnamed
Year:
2004
Report date:
2004

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 471 (Bacterial Reverse Mutation Assay)
Qualifier:
according to guideline
Guideline:
EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
GLP compliance:
yes (incl. QA statement)
Type of assay:
bacterial reverse mutation assay

Test material

Constituent 1
Chemical structure
Reference substance name:
-
EC Number:
456-160-0
EC Name:
-
Cas Number:
73942-87-7
Molecular formula:
C12H13NO3
IUPAC Name:
7,8-dimethoxy-2,3-dihydro-1H-3-benzazepin-2-one

Method

Species / strain
Species / strain / cell type:
S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
Metabolic activation:
with and without
Metabolic activation system:
The S9 mix consists of induce enzymatic systems contained in rat liver post-mitochondrial fraction and tehe cofactors necessary for their function.
Test concentrations with justification for top dose:
Range: 312,5 - 5000 µg/plate

Results and discussion

Any other information on results incl. tables

No toxicity was noted towards all the strains used, with and without S9 mix.

Applicant's summary and conclusion

Conclusions:
Under the experimental conditions, Veralactama did not show mutagenic activity in the bacterial reverse mutation test with Salmonella typhimurium.